Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.42 HKD | +1.43% | +4.41% | -2.74% |
04-03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
04-03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
- Stock Market
- Equities
- 1672 Stock
- News Ascletis Pharma Inc.
- Other languages